Cargando…

Imaging prior to radiotherapy impacts in-vitro survival

BACKGROUND AND PURPOSE: Cone Beam Computed Tomography (CBCT) is routinely used in radiotherapy to identify the position of the target volume. The aim of this study was to determine whether the CBCT dose, when followed by the treatment, influences the therapeutic outcomes as determined by in-vitro cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kench, Peter L., Rogers, Linda, Esteves, Ana, Gorjiara, Tina, Mackonis, Elizabeth Claridge, Morrell, Stephen, McKenzie, David R., Suchowerska, Natalka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807556/
https://www.ncbi.nlm.nih.gov/pubmed/33458357
http://dx.doi.org/10.1016/j.phro.2020.11.003
_version_ 1783636766219042816
author Kench, Peter L.
Rogers, Linda
Esteves, Ana
Gorjiara, Tina
Mackonis, Elizabeth Claridge
Morrell, Stephen
McKenzie, David R.
Suchowerska, Natalka
author_facet Kench, Peter L.
Rogers, Linda
Esteves, Ana
Gorjiara, Tina
Mackonis, Elizabeth Claridge
Morrell, Stephen
McKenzie, David R.
Suchowerska, Natalka
author_sort Kench, Peter L.
collection PubMed
description BACKGROUND AND PURPOSE: Cone Beam Computed Tomography (CBCT) is routinely used in radiotherapy to identify the position of the target volume. The aim of this study was to determine whether the CBCT dose, when followed by the treatment, influences the therapeutic outcomes as determined by in-vitro clonogenic cell survival in a radiobiological experiment. MATERIALS AND METHODS: Human cell lines, four cancer and one normal, were exposed to a 6 MV photon beam, produced by a linear accelerator. For half of each sample, a prior imaging dose was delivered using the on-board CBCT. A sample size of n = 103 was used to achieve statistical power. RESULTS: The experimental group of cell lines exposed to CBCT imaging prior to treatment exhibited a reduction in mean cancer cell survival of ~17 times (p = 0.02) greater than predicted from the average dose response and equivalent to more than 5% of the therapeutic dose, compared to 11 times greater than predicted for normal cells (n.s.). CONCLUSION: The greater than predicted reduction in survival resulting from the additional CBCT dose is consistent with radiation-induced bystander effects.
format Online
Article
Text
id pubmed-7807556
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-78075562021-01-14 Imaging prior to radiotherapy impacts in-vitro survival Kench, Peter L. Rogers, Linda Esteves, Ana Gorjiara, Tina Mackonis, Elizabeth Claridge Morrell, Stephen McKenzie, David R. Suchowerska, Natalka Phys Imaging Radiat Oncol Original Research Article BACKGROUND AND PURPOSE: Cone Beam Computed Tomography (CBCT) is routinely used in radiotherapy to identify the position of the target volume. The aim of this study was to determine whether the CBCT dose, when followed by the treatment, influences the therapeutic outcomes as determined by in-vitro clonogenic cell survival in a radiobiological experiment. MATERIALS AND METHODS: Human cell lines, four cancer and one normal, were exposed to a 6 MV photon beam, produced by a linear accelerator. For half of each sample, a prior imaging dose was delivered using the on-board CBCT. A sample size of n = 103 was used to achieve statistical power. RESULTS: The experimental group of cell lines exposed to CBCT imaging prior to treatment exhibited a reduction in mean cancer cell survival of ~17 times (p = 0.02) greater than predicted from the average dose response and equivalent to more than 5% of the therapeutic dose, compared to 11 times greater than predicted for normal cells (n.s.). CONCLUSION: The greater than predicted reduction in survival resulting from the additional CBCT dose is consistent with radiation-induced bystander effects. Elsevier 2020-11-28 /pmc/articles/PMC7807556/ /pubmed/33458357 http://dx.doi.org/10.1016/j.phro.2020.11.003 Text en © 2020 The Authors. Published by Elsevier B.V. on behalf of European Society of Radiotherapy & Oncology. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research Article
Kench, Peter L.
Rogers, Linda
Esteves, Ana
Gorjiara, Tina
Mackonis, Elizabeth Claridge
Morrell, Stephen
McKenzie, David R.
Suchowerska, Natalka
Imaging prior to radiotherapy impacts in-vitro survival
title Imaging prior to radiotherapy impacts in-vitro survival
title_full Imaging prior to radiotherapy impacts in-vitro survival
title_fullStr Imaging prior to radiotherapy impacts in-vitro survival
title_full_unstemmed Imaging prior to radiotherapy impacts in-vitro survival
title_short Imaging prior to radiotherapy impacts in-vitro survival
title_sort imaging prior to radiotherapy impacts in-vitro survival
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807556/
https://www.ncbi.nlm.nih.gov/pubmed/33458357
http://dx.doi.org/10.1016/j.phro.2020.11.003
work_keys_str_mv AT kenchpeterl imagingpriortoradiotherapyimpactsinvitrosurvival
AT rogerslinda imagingpriortoradiotherapyimpactsinvitrosurvival
AT estevesana imagingpriortoradiotherapyimpactsinvitrosurvival
AT gorjiaratina imagingpriortoradiotherapyimpactsinvitrosurvival
AT mackoniselizabethclaridge imagingpriortoradiotherapyimpactsinvitrosurvival
AT morrellstephen imagingpriortoradiotherapyimpactsinvitrosurvival
AT mckenziedavidr imagingpriortoradiotherapyimpactsinvitrosurvival
AT suchowerskanatalka imagingpriortoradiotherapyimpactsinvitrosurvival